scholarly journals Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Gregory Byrd ◽  
Sabina Custovic ◽  
David Byrd ◽  
Deanna Ingrassia Miano ◽  
Jasdeep Bathla ◽  
...  
Keyword(s):  
Platelet Activation ◽  
Cardiac Catheterization ◽  
Platelet Transfusion ◽  
Case Reports ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Airway Protection ◽  
Case Presentation ◽  
Receptor Inhibitor

Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent pathways which cause thrombocytopenia upon subsequent reexposure to eptifibatide. This case reports acute profound thrombocytopenia ( platelets < 20 × 10 3 / m m 3 ) within 24 hours of administration. Alveolar hemorrhage occurred during a second eptifibatide infusion 5 days after initial asymptomatic eptifibatide treatment. Case Presentation. A 50-year-old male presenting with a STEMI was treated with eptifibatide during cardiac catheterization. Twelve hours posttreatment, the patient encountered profound thrombocytopenia and hemoptysis. The patient was briefly intubated for airway protection. The patient was stabilized after receiving platelet transfusion and fully recovered. Conclusion. This is one of several cases reported on eptifibatide causing acute profound thrombocytopenia and subsequent alveolar hemorrhage. This case supports the theory in which antibodies contribute to eptifibatide-induced thrombocytopenia.

scholarly journals Idiopathic Pulmonary Hemosiderosis in an Adult with Unusual Radiologic Features

2014 ◽  
Vol 48 (4) ◽  
pp. 199-200
Author(s):  
Sangeeth Kumar Kasilingam ◽  
Shylaja Prashanth ◽  
Manjunath B Govindagoudar ◽  
Bheemaraya Devaramani ◽  
Chaitra Channarayapatna Swamygowda
Keyword(s):  
Case Reports ◽  
Ground Glass Opacity ◽  
Diffuse Alveolar Hemorrhage ◽  
Acute Episode ◽  
Alveolar Hemorrhage ◽  
Severe Anemia ◽  
Pulmonary Hemosiderosis ◽  
Idiopathic Pulmonary Hemosiderosis ◽  
In Infants And Children ◽  
Radiologic Features

ABSTRACT Idiopathic pulmonary hemosiderosis is an exceptionally rare cause of diffuse alveolar hemorrhage that occurs primarily in infants and children. Few cases are reported in adults. Patients usually present with recurrent episodes of hemoptysis, fatigue breathlessness and severe anemia with asymptomatic periods in between. Our patient, who was diagnosed with idiopathic pulmonary hemosiderosis demonstrated diffuse ground glass opacity, focal centrilobular emphysema and multiple sub pleural cysts and few parenchymal cysts during acute episode of hemoptysis. Unusual findings in our case were sub pleural cysts, parenchymal cysts and focal centrilobular emphysema which was not documented in any case reports of idiopathic pulmonary hemosiderosis cases to that of our knowledge. How to cite this article Kasilingam SK, Prashanth S, Govindagoudar MB, Devaramani B, Swamygowda CC. Idiopathic Pulmonary Hemosiderosis in an Adult with Unusual Radiologic Features. J Postgrad Med Edu Res 2014;48(4):199-200.

scholarly journals Diffuse Alveolar Hemorrhage after Receiving Oral Levonorgerstrel for Emergency Contraception: A Case Report

2021 ◽  
Vol 14 ◽  
pp. 117954762110058
Author(s):  
Athina Georgopoulou ◽  
Efthymia Papadopoulou ◽  
Marianna Moyseos ◽  
Sofia-Chrysovalantou Zagalioti ◽  
Christos Hatzis ◽  
...  
Keyword(s):  
Emergency Contraception ◽  
Pathological Condition ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Causative Role ◽  
Drug Induced ◽  
Case Presentation ◽  
Pathological Conditions ◽  
Emergency Contraceptive

Introduction: Drug-induced diffuse alveolar hemorrhage (DAH) has been associated with the administration of various medications, among which levonorgestrel (LN) has not been reported until now. Case Presentation: This case study describes a 42-year-old woman who presented with hemoptysis, hypoxemia, and radiological depiction of ground glass opacities, 3 days after she had received emergency contraceptive medication containing levonorgestrel. Emergent bronchoscopy was performed, and BAL was diagnostic of diffuse alveolar hemorrhage (DAH). A thorough diagnostic approach was followed, in order to detect the underlying pathological condition that induced DAH. The absence of other identifiable pathological conditions in this patient raised suspicion of LN’s potential causative role. Conclusion: DAH has not been reported as an adverse effect of LN until now. However, LN has been found to exert immunomodulatory effects and to present potential for manifestations of vasculitis as well as severe hypersensitivity reactions. These mechanisms may have been implicated in the development of DAH in our patient, who presented no other pathological conditions.

Diffuse alveolar hemorrhage associated with ustekinumab treatment

2021 ◽  
Author(s):  
Kulothungan Gunasekaran ◽  
Anant Shukla ◽  
Nageshwari Palanisamy ◽  
Mandeep Singh Rahi ◽  
Armand Wolff
Keyword(s):  
Temporal Relationship ◽  
Case Reports ◽  
Rare Complication ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Drug Discontinuation ◽  
Computed Tomography Scan ◽  
First Case ◽  
Lupus Syndrome ◽  
Tomography Scan

Abstract Purpose A case of diffuse alveolar hemorrhage (DAH) occurring as a reaction to ustekinumab therapy is reported. Summary After starting ustekinumab for treatment of psoriatric arthritis, a 46-year-old female presented with flu-like symptoms and cough with blood-tinged sputum that had begun 1 week previously. Her initial computed tomography scan of the chest demonstrated bilateral ground-glass opacities. On bronchoscopy, the bronchoalveolar lavage (BAL) return became bloodier from sample 1 to samples 2 and 3. Her BAL fluid was more than 90% hemosiderin-laden macrophages, a finding consistent with DAH. We ruled out infectious etiologies and other common vasculitis conditions that can cause DAH. A diagnosis of ustekinumab-induced DAH was made due to a temporal relationship between initiation of the drug and the patient’s presentation and the absence of infection and other alternate diagnosis. Prior case reports including ustekinumab-induced pneumonitis, interstitial lung disease with a granulomatous component, and lupus syndrome have been reported, with this being the first case of DAH in a patient undergoing treatment of psoriatic arthritis. Conclusion A 46-year-old woman developed DAH during ustekinumab treatment. Symptoms abated after drug discontinuation and supportive treament. Clinicians must remain mindful of this rare complication of ustekinumab use in order to avoid potential delays in appropriate DAH treatment.

scholarly journals Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Dania Khoulani ◽  
Bharat Rao ◽  
Ammar Khanshour ◽  
Philip Kuriakose ◽  
Lenar Yessayan
Keyword(s):  
Case Reports ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Factor Vii ◽  
Small Vessel Vasculitis ◽  
Cryoglobulinemic Vasculitis ◽  
Recombinant Activated Factor Vii ◽  
Randomized Controlled ◽  
Activated Factor Vii ◽  
Life Threatening

Diffuse alveolar hemorrhage (DAH) is a serious complication of the small vessel vasculitis syndromes and carries a high mortality. Recombinant activated factor VII (rFVIIa) is used to treat bleeding in patients with hemophilia and antibodies to factor VIII or IX. It is increasingly being used in life-threatening hemorrhage in a variety of other settings in which conventional therapy is unsuccessful. Randomized controlled trials of rFVIIa in DAH are lacking. However, several case reports have described a complete or sustained control of DAH using rFVIIa after patients failed to respond to medical treatment. There are no case reports in the literature describing the use or the failure of rFVIIa in DAH associated with cryoglobulinemic vasculitis. We here report the failure of rFVIIa to control DAH in a patient with CD5+ B-cell non-Hodgkin’s lymphoma and cryoglobulinemic vasculitis.

scholarly journals Diffuse Alveolar Hemorrhage Induced by Vaping

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Michael Agustin ◽  
Michele Yamamoto ◽  
Felix Cabrera ◽  
Ricardo Eusebio
Keyword(s):  
Hypersensitivity Pneumonitis ◽  
Case Reports ◽  
Young Male ◽  
Pulmonary Complications ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Innovative Technology ◽  
Cigarette Use ◽  
Alveolar Capillary

There has been a significant increase in electronic cigarette (e-cigarette) use since its introduction in 2007. Ironically, there remains very few published literature on the respiratory complications of e-cigarettes. The use of personalized vaporizers or commonly known as “vaping” has started to overtake standard e-cigarette. Its dynamic vaporizer customization makes it challenging to assess long-term health effects. Case reports on the pulmonary complications of e-cigarettes are limited to bronchiectasis, eosinophilic pneumonia, pleural effusion, and suspected hypersensitivity pneumonitis. Diffuse alveolar hemorrhage (DAH) is bleeding into the alveolar spaces of the lung secondary to disruption of the alveolar-capillary basement membrane. We report a case of young male presenting with subacute respiratory failure. He was later found to have diffuse alveolar hemorrhage syndrome that is likely induced by aggressive vaping. This adds up to the rising concern on the possible serious complications of this innovative technology designed as a safer alternative to traditional cigarettes.

scholarly journals A Rare Case of Diffuse Alveolar Hemorrhage Secondary to Acute Pulmonary Histoplasmosis

2015 ◽  
Vol 2015 ◽  
pp. 1-4
Author(s):  
Kunal Grover ◽  
Hadeel Zainah ◽  
Shubhita Bhatnagar ◽  
Tricia Stein
Keyword(s):  
Rare Case ◽  
English Language ◽  
Case Reports ◽  
Diffuse Alveolar Hemorrhage ◽  
Initial Presentation ◽  
Alveolar Hemorrhage ◽  
Adult Case ◽  
Rare Presentation ◽  
Pulmonary Histoplasmosis ◽  
Language Literature

Diffuse alveolar hemorrhage (DAH) is a rare presentation of acute pulmonary histoplasmosis. While histoplasmosis has been reported to cause hemoptysis and alveolar hemorrhage in children, the English language literature lacks any adult case reports documenting this association. We report a case of pulmonary histoplasmosis where the initial presentation was pneumonia with a subsequent diagnosis of DAH.

scholarly journals A Case of Pulmonary Tuberculosis Mimicking as Diffuse Alveolar Hemorrhage: A case report

2021 ◽  
Vol 02 ◽  
Author(s):  
Trilok Chand ◽  
Georgie Thomas ◽  
M. U. Khan
Keyword(s):  
Pulmonary Tuberculosis ◽  
Autoimmune Disorder ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
First Line ◽  
Case Presentation ◽  
The World ◽  
Anti Tubercular Therapy ◽  
Specific Reason

Background: Pulmonary tuberculosis (TB) and diffuse alveolar hemorrhage (DAH) have some commonalities in several parts of the world. However, acute hemoptysis with diffuse alveolar shadows while a patient is on anticoagulant and antiplatelet therapy for a specific reason suggests DAH over TB. Case Presentation: In this case, a patient was presented with acute respiratory symptoms with hypoxia and bilateral alveolar shadows. He was treated for DAH at the initial encounter. However, on follow-up, he was confirmed having active pulmonary TB based on sputum acid-fast-bacilli culture. Conclusion: He was successfully treated with standard first-line anti-tubercular therapy and was subsequently declared cured. Pulmonary DAH with TB, in the absence of an underlying autoimmune disorder, is rare.

Sign in / Sign up

Export Citation Format

Share Document